Biological Dynamics of Forest Fragments Project

New Study Using Biological Dynamics’ ExoVerita Platform Validates Exosome Detection of Early-Stage Pancreatic Ductal Adenocarcinoma (PDAC)

Retrieved on: 
Thursday, October 19, 2023
Managed Care, Research, Other Health, Oncology, Medical Devices, Infectious Diseases, Genetics, Surgery, Clinical Trials, Science, Biotechnology, Health, Other Science, Neoplasm, Survival, Biomarker, II, Oregon Health & Science University, Exosome, Detection, Cell, Nanoparticle, Biological Dynamics of Forest Fragments Project, Disease, Cancer, OHSU, Machine learning, Survival rate, Pancreatic cancer, PDAC, Pharmaceutical industry, Medical imaging, Verita

Biological Dynamics, Inc., a leader in exosome-isolation technology for early disease detection, announced a newly published study in Nature’s Communications Medicine titled “ Development of a Blood-Based EV Classifier for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma .” The research demonstrates the effectiveness of exosome-isolation technology in detecting Stage I and II pancreatic ductal adenocarcinoma (PDAC), using an independent validation cohort.

Key Points: 
  • Biological Dynamics, Inc., a leader in exosome-isolation technology for early disease detection, announced a newly published study in Nature’s Communications Medicine titled “ Development of a Blood-Based EV Classifier for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma .” The research demonstrates the effectiveness of exosome-isolation technology in detecting Stage I and II pancreatic ductal adenocarcinoma (PDAC), using an independent validation cohort.
  • Biological Dynamics’ ExoVita Pancreas assay, powered by the ExoVerita™ platform, uses the AC Electrokinetics method for exosome isolation.
  • “Driven by our Verita technology, the ExoVita test can detect challenging diseases like pancreatic cancer earlier than ever.
  • With further testing in real-world settings, we are confident our exosome enabled test will be useful for high-risk surveillance and early detection of pancreatic cancer, resulting in improved patient outcomes.”

Biological Dynamics to Highlight ExoLuminate Study for Early Detection of Pancreatic Cancer in High-Risk Populations at ASCO Annual Meeting

Retrieved on: 
Friday, June 2, 2023
Oncology, Health, Health Technology, Clinical Trials, Research, Science, Biotechnology, PDAC, Pancreatic cancer, Biological Dynamics of Forest Fragments Project, Principal investigator, Survival, Cancer, Pancreas, Doctor of Philosophy, Biology, II, ASCO, American Society of Clinical Oncology, Medical director, Risk, Master of Science, Exosome, Society, Medical imaging, Pharmaceutical industry, MD

The detection of pancreatic ductal adenocarcinoma (PDAC) at early-stages is critical to improving patient survival.

Key Points: 
  • The detection of pancreatic ductal adenocarcinoma (PDAC) at early-stages is critical to improving patient survival.
  • Today, Biological Dynamics’ liquid biopsy offering, ExoVita™ Pancreas, targets and isolates exosomes from patients’ blood samples to detect the likelihood of developing PDAC.
  • Early studies show that the assay can detect pancreatic cancer at stages I and II, with high sensitivity and specificity.
  • “The ExoLuminate study will further validate our assay, along with generating evidence of early disease in people who are at a higher risk for developing pancreatic cancer.

Biological Dynamics to Present Data at AACR Highlighting ExoVerita Platform-Enabled Earlier Detection of Pancreatic and Lung Cancers

Retrieved on: 
Friday, April 14, 2023
Research, General Health, Radiology, Oncology, Biometrics, Medical Devices, Genetics, Health Technology, Clinical Trials, Science, Biotechnology, Health, PDAC, Pancreatic cancer, AACR, Biological Dynamics of Forest Fragments Project, Survival, Exosome, Cancer, Lung cancer, Biomarker, IPMN, EDT, Lung, EVS, Liquid biopsy, Seminal vesicles, Medical director, Pancreas, Risk, Acute pancreatitis, Master of Science, American Association for Cancer Research, Medical imaging, MD

Biological Dynamics’ will exhibit its technology and early cancer detection assays at booth #1368.

Key Points: 
  • Biological Dynamics’ will exhibit its technology and early cancer detection assays at booth #1368.
  • “Pancreatic and lung cancers are two of the deadliest cancers in the U.S., as they are often diagnosed in late stages, making treatment more difficult and lowering survival chances.
  • Results show that Biological Dynamics’ lung assay, performed on the ExoVerita platform, detected cancer with an overall sensitivity and specificity of approximately 91%.
  • The presented data suggest the potential for the company’s technology and assays to become an integral component of surveillance for and early detection of cancers.

Biological Dynamics Appoints Zach Miller to Board of Directors

Retrieved on: 
Tuesday, March 7, 2023
Science, Biotechnology, Research, Surgery, Oncology, Health, Clinical Trials, Other Health, Slate, Tiger Global Management, Philosophy, Biological Dynamics of Forest Fragments Project, Bain Capital, Worcester College, Oxford, University of Oxford, Growth, Miller, Pancreatic cancer, Partnership, Patient, Williams College, Information technology, Biology, Pharmaceutical industry

Biological Dynamics, Inc. , an emerging growth life sciences company commercializing its ExoVerita™ platform for exosome-isolation and ExoVita™ Pancreas assay for the early detection of pancreatic cancer, has appointed Zach Miller as a member of its Board of Directors.

Key Points: 
  • Biological Dynamics, Inc. , an emerging growth life sciences company commercializing its ExoVerita™ platform for exosome-isolation and ExoVita™ Pancreas assay for the early detection of pancreatic cancer, has appointed Zach Miller as a member of its Board of Directors.
  • Miller will provide strategic guidance and direction for the Company as it enters a period of rapid growth and commercial operations.
  • Miller holds a bachelor’s degree, summa cum laude, from Williams College and a master’s degree in philosophy with distinction from Worcester College, Oxford University.
  • “I am honored to join Biological Dynamics’ Board of Directors and look forward to supporting the Company’s mission to provide groundbreaking diagnostic solutions for early disease detection,” Miller said.

Biological Dynamics and Oregon Health & Science University Collaborate on Early-Stage Pancreatic Cancer Detection Study

Retrieved on: 
Wednesday, March 1, 2023
Oncology, Health, Surgery, Clinical Trials, Research, Science, Biotechnology, Oregon Health and Science University Center for Women's Health, Oregon Health & Science University, Biological Dynamics of Forest Fragments Project, Doctor of Philosophy, Quality of life, MD, Survival, Diagnosis, PDAC, Sheppard, Pancreatic cancer, Disease, Partnership, Biomarker, Pancreas, Patient, DRS, Sears, Pancreatic cyst, Medical genetics, Neoadjuvant therapy, OHSU, Blood, Biology, FACS, Pharmaceutical industry

Biological Dynamics, Inc. , a company developing and commercializing its exosome-isolation ExoVerita™ platform for early disease diagnostics and other applications, announced its collaboration with the Brenden-Colson Center for Pancreatic Care at Oregon Health & Science University (OHSU) to study its ExoVita™ Pancreas assay.

Key Points: 
  • Biological Dynamics, Inc. , a company developing and commercializing its exosome-isolation ExoVerita™ platform for early disease diagnostics and other applications, announced its collaboration with the Brenden-Colson Center for Pancreatic Care at Oregon Health & Science University (OHSU) to study its ExoVita™ Pancreas assay.
  • The Brenden-Colson Center has a robust, integrated clinical-translational interface to drive innovative patient care and nourish scientific collaborations.
  • The ExoVita Pancreas assay significantly improves the care of patients at high risk for pancreatic cancer through earlier detection.
  • “We have a long-standing relationship with Oregon Health & Science University and look forward to collaborating to evaluate the clinical validity of our ExoVita Pancreas test,” said Paul Billings, MD, PhD, CEO of Biological Dynamics.

Biological Dynamics collaborates on clinical utility studies to examine the impact of its early pancreatic cancer detection assay

Retrieved on: 
Wednesday, November 23, 2022
Patient, CPV, Food, Physician, Biological Dynamics of Forest Fragments Project, Behavior, FACP, Quality of life, CMO, Partnership, AACC, Regulation of tobacco by the U.S. Food and Drug Administration, Health, Seminal vesicles, SAN, University of California, Irvine Medical Center, Pancreatic cancer, Randomized controlled trial, University, PDAC, CAP, Survival, Cancer, Medicine, Pharmaceutical industry, Medical imaging, Curta

SAN DIEGO, Nov. 22, 2022 /PRNewswire/ -- Biological Dynamics, an exosome-isolation technology and early disease detection diagnostic company, today announced that it has partnered with both QURE Healthcare and Curta to explore how the company's assay for early detection of pancreatic ductal adenocarcinoma (PDAC) can improve patient outcomes, demonstrate the greatest value to clinicians, and enhance healthcare economics.

Key Points: 
  • Therefore, Biological Dynamics will help conduct independent studies on how providers will use its early PDAC detection assay and how the test performance and cost may impact downstream patient care and curative interventions that payors review for reimbursement coverage decisions.
  • "We must more fully understand the risks and benefits of early detection methods in all individuals including those at high-risk for pancreatic cancer.
  • The Curta study for Biological Dynamics will explore the potential health and economic outcomes of early PDAC detection with the Biological Dynamics' PDAC assay from a US payor perspective.
  • Its AACC award-winning PDAC assay operates in a College of American Pathologists (CAP) accredited, CLIA-certified clinical laboratory in San Diego.

Small Pharma Strengthens Board With Appointment of Paul Maier as Independent Director

Retrieved on: 
Thursday, November 18, 2021
Committee, Financial compensation, Harvard Graduate School of Arts and Sciences, Indian stock exchange, Corporate governance, Â, Brain, Apricus Biosciences, Company, DMT, Audit committee, Ligand Pharmaceuticals, MBA, MDD, ISCO, Leadership, Imperial College London, Business, Program, Biological Dynamics of Forest Fragments Project, Pharma, Plant, CDN, OTCBB, GLOBE, Sequenom, Board, N, Depression, Option, Mammal, NASDAQ, Growth, Initial public offering, IP, Security (finance), Pharmaceutical industry

LONDON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the Company or Small Pharma), a neuropharmaceutical company focused on psychedelic-assisted therapies, announces that Mr. Paul Maier has been appointed as a non-executive independent director of the board of directors of the Company (the Board).

Key Points: 
  • LONDON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the Company or Small Pharma), a neuropharmaceutical company focused on psychedelic-assisted therapies, announces that Mr. Paul Maier has been appointed as a non-executive independent director of the board of directors of the Company (the Board).
  • Mr. Maier joins Small Pharma with over 30 years experience in senior executive roles across the biopharmaceutical and biotech industry.
  • Lyne Fortin, Chair of the Board of Small Pharma, said: We are delighted to welcome someone of Pauls calibre to the Board of Small Pharma.
  • Mr. Maier added: It is an honor to join the Small Pharma Board at this exciting juncture for the Company.